Abstract
B-lymphocyte stimulator (BLyS) plays a critical role in the survival of B-lymphocytes. In 50 patients with Hodgkin's lymphoma BLyS levels were higher in newly diagnosed patients (median 2.0 ng/mL, range <0.3-56.0) and relapsed patients (8.7 ng/mL, range 1.5-71.5) than in 93 healthy donors (<0.3 ng/mL, range <0.3-0.5). High serum BLyS levels (≥2.0 ng/mL) in newly diagnosed patients were associated with resistance to therapy (p=0.01) and shorter progression-free survival (log-rank p=0.029, 2-year rate 64% vs 100%). Serum BLyS levels may have prognostic significance in Hodgkin's lymphoma.
Original language | English (US) |
---|---|
Pages (from-to) | 269-270 |
Number of pages | 2 |
Journal | Haematologica |
Volume | 92 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2007 |
Keywords
- BLyS
- Hodgkin's lymphoma
- Prognostic factor
ASJC Scopus subject areas
- Hematology